Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03580707 · ClinicalTrials.gov registry record · Phase 2
Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint
A Phase 2 study of Photosensitive Epilepsy, sponsored by Rosenfeld, William E., M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03580707: Completed Phase 2 study of Photosensitive Epilepsy, sponsored by Rosenfeld, William E., M.D..
NCT03580707 is a Phase 2 study of Photosensitive Epilepsy that has completed, run by Rosenfeld, William E., M.D.. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03580707, a Phase 2 study of Photosensitive Epilepsy, has completed, sponsored by Rosenfeld, William E., M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to see whether brivaracetam has a faster onset time and greater effect than levetiracetam in subjects with photosensitive seizures. Part 1 of the study will compare the effects of levetiracetam 1500 mg with the effects of brivaracetam 100 mg. Part 2, will compare the effects of levetiracetam 1500 mg with the effects of brivaracetam 100 mg or will compare the effects of levetiracetam 500mg with the effects of brivaracetam 25 mg.
Primary Outcome
Difference in time (minutes) required between drugs, BRV\& LEV to abolish a PPR (photo-paroxysmal response on the pts encephalogram, EEG) after intermittent photic stimulation (IPS) tested in the same pt of 2 separate occasions. In Pt 1, 8 pts w/photosensitive epilepsy will be studied in double-blind, crossover fashion with 15-minute linear intravenous (i.v.) infusion of either 1500 mg LEV or BRV 100 mg as single dose. After 2 weeks, each pt will be tested in identical fashion w/opposite drug (c
Conditions Studied
Interventions
- DRUG BRV vs LEV in randomized double blinded, crossover fashion
Study Locations (1)
Missouri
- The Comprehensive Epilepsy Care Center For Children And Adults - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
What the finished NCT03580707 record still lists
NCT03580707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Photosensitive Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which BRV vs LEV in randomized double blinded, crossover fashion is the first listed.
NCT03580707 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03580707 about?
NCT03580707 is a clinical study titled "Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint". The main purpose of this study is to see whether brivaracetam has a faster onset time and greater effect than levetiracetam in subjects with photosensitive seizures. Part 1 of the study will compare the effects of levetiracetam 1500 mg with the effects of brivaracetam 100 mg. Part 2, will compare th...
What is the current status of trial NCT03580707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-06-01. Estimated completion is 2018-12-31.
What conditions does trial NCT03580707 study?
This clinical trial studies the following conditions: Photosensitive Epilepsy.
What interventions are being tested in trial NCT03580707?
The interventions under investigation include: BRV vs LEV in randomized double blinded, crossover fashion (DRUG).
Who is sponsoring clinical trial NCT03580707?
This trial is sponsored by Rosenfeld, William E., M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03580707 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03580707's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI